Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some safety/efficacy claims are supported by the provided label excerpts (schizophrenia indication, QT prolongation, orthostatic hypotension/syncope with dizziness, weight gain). Several other adverse effect and counseling/discontinuation statements are not supported by the provided label sections or lack label evidence in the material supplied.
Category Scores
Accurate Statements
Fanapt (iloperidone) is used to control schizophrenia symptoms.
1 INDICATIONS AND USAGE: Treatment of schizophrenia in adults.
Fanapt may cause dizziness or lightheadedness.
5.7 Orthostatic Hypotension and Syncope: orthostatic hypotension associated with dizziness; prescriber evaluation if symptoms could indicate cardiac arrhythmias including dizziness.
Fanapt can affect blood pressure in some patients, making dizziness or faintness important to watch for.
5.7 Orthostatic Hypotension and Syncope (orthostatic hypotension associated with dizziness and syncope); 17 PATIENT COUNSELING INFORMATION (risk of orthostatic hypotension and syncope).
Fanapt can affect heart rhythm (QT interval).
5.3 QT Prolongation: FANAPT associated with QTc prolongation.
Fanapt may be started and increased carefully due to its effect on the QT interval.
Partial support: 5.3 QT Prolongation describes QTc risk; however the provided dosage/titration instruction specifically states titration to avoid orthostatic hypotension (2.1), not QT interval management.
Unsupported Statements
Fanapt may cause sedation or sleepiness.
No sedation/somnolence statement supported by the provided label excerpts.
Fanapt may cause weight gain and increased appetite.
Weight gain is supported (17 PATIENT COUNSELING INFORMATION: weight gain has occurred), but increased appetite is not supported by the provided excerpts.
Fanapt may cause dry mouth.
Dry mouth not supported by the provided label excerpts.
Fanapt may cause constipation.
Constipation not supported by the provided label excerpts.
Clinicians may order ECGs or perform cardiac monitoring after starting or changing Fanapt dose.
Provided label language in 5.3 supports additional evaluation/cardiac monitoring when symptoms suggest arrhythmias; it does not explicitly state ECG/monitoring after starting or dose change.
Fanapt dosing changes may be associated with increased dizziness or significant dizziness.
Label supports orthostatic hypotension/syncope risk particularly at initiation/re-initiating/increasing dose, but the provided excerpts do not specifically state that dizziness severity or frequency increases with dosing changes.
Fanapt is an antipsychotic.
The provided excerpts do not explicitly label FANAPT as an antipsychotic (only references to antipsychotic-related warnings/cases).
Fanapt may be more sedating than some alternative antipsychotics (as reported by some people).
No comparative sedating/effectiveness-by-comparison statements supported by the provided excerpts.
Fanapt may be less sedating than some alternative antipsychotics (as reported by some people).
No comparative sedating/effectiveness-by-comparison statements supported by the provided excerpts.
Dizziness/lightheadedness commonly comes up in reviews for Fanapt.
Label does not discuss 'reviews' or comparative frequency phrasing like 'commonly comes up in reviews.'
Weight changes are a frequent comparison point across antipsychotics.
Label does not include comparative/market-level statements about how frequently weight is discussed across antipsychotics.
People may stop or switch Fanapt due to side effects that are hard to manage, including sleepiness, dizziness, and weight gain.
The provided excerpts support dizziness/orthostatic hypotension and weight gain, but do not support sleepiness or generalized statements about stopping/switching due to these reasons.
People may stop or switch Fanapt due to not enough symptom improvement at the dose/timeline tried.
No label support for patient discontinuation/switching rationale based on inadequate symptom response at a specific dose/timeline.
People may stop or switch Fanapt due to needing a different medication due to tolerability or personal preference.
No label support for switching based on tolerability/personal preference.
Stopping Fanapt should be discussed with a prescriber rather than stopped abruptly.
No discontinuation/abrupt stopping counseling statement found in the provided excerpts.
Contradictions
Important Omissions
Key label domains not provided for audit: boxed warnings, contraindications, full warnings/precautions beyond QT and orthostatic hypotension, and specific-population sections (e.g., pregnancy/lactation, elderly/dementia-related, pediatric).
Importance:
High
For QT-related risk mitigation, the claim set does not include the label’s explicit advice to avoid coadministration with other QT-prolonging drugs and to avoid FANAPT in patients with certain histories/genetic susceptibility; monitoring recommendations are only partially reflected.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims (e.g., sedation/sleepiness, dry mouth, constipation) and partially supported monitoring statements could mislead counseling. Several important safety elements (boxed warnings/contraindications and broader warnings) could not be verified due to missing label sections, limiting overall label adherence confidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple adverse effect and counseling/discontinuation claims are not supported by the provided label excerpts; several QT/monitoring statements are broader than the label language shown.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label sections (e.g., weight gain; orthostatic hypotension/syncope; QT prolongation). Replace review/comparative/switching/discontinuation statements with label-supported counseling. Align QT-related monitoring language with label wording (symptom-triggered evaluation/cardiac monitoring) and include explicit avoidance of QT-prolonging combinations per the provided QT section.